toxSYN™ ADC Payload Platform
The toxSYN™ platform comprises ADC payloads that span multiple modes of action and where the majority are clinically validated. Together with the company’s other ADC enabling technologies, these offer a consolidated licensing solution for translating any antibody into a highly competitive, proprietary ADC product.
Each toxSYN™ linker-payload is functionalized to allow facile conjugation using the company’s GlycoConnect™ technology. Furthermore, these may include linkers that are of non-cleavable or cleavable nature (i.e. designed for intracellular/lysosomal release of the active catabolite).
|Topoisomerase inhibition||SYNtecan™ P||undisclosed
|SYNeamicin D™ P||calicheamicin γ1I|
|SYNeamicin G™ P||calicheamicin γ1I|
|Microtubule inhibition||SYNstatin E™||MMAE|
P Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™
PLEASE NOTE: these illustrations represent an artist’s rendition